Mepolizumab in Episodic Angioedema With Eosinophilia
Mots clés
Abstrait
La description
Episodic angioedema with eosinophilia (EAE), also known as Gleich s Syndrome,is a rare disorder characterized by recurrent episodes of urticaria, fever, angioedema, weight gain and dramatic eosinophilia that occur at 3- to 6-week intervals and resolve with spontaneous diuresis in the absence of therapy. Although the syndrome is often classified in the broad category of idiopathic hypereosinophilic syndrome (HES), EAE is a distinct eosinophilic syndrome that is remarkably homogeneous in clinical presentation. More recently, it has become apparent that there is multilineage cycling, involving lymphocytes and neutrophils in addition to eosinophils. Early studies described cyclic elevations of serum interleukin 5 (IL-5) preceding the rise in eosinophilia, and additional studies have shown cyclic elevations in other type II cytokines as well as in eosinophilic chemokines. Aberrant T cells with a CD3-CD4+ surface phenotype have also been detected in the majority of subjects with EAE. The cyclic nature of the disorder and the involvement of multiple cell lineages have made it difficult to determine the underlying cause of EAE.
We hypothesize that IL-5 driven eosinophilia is central to the pathogenesis of EAE. Suppression of eosinophil cycling by blocking IL-5 would help determine whether eosinophils are indeed the main drivers of the symptoms of angioedema and urticaria and pave the way for future mechanistic studies investigating the etiology of this unusual disorder. The purpose of this pilot study is to evaluate the effect of mepolizumab, a humanized antibody to IL-5, on eosinophil cycling in 12 subjects with EAE. Subjects with EAE will undergo screening on the National Institutes of Health protocol 94-I-0079 to establish the periodicity of their cycling (if not previously determined) and the optimal timing for the baseline visit. After screening, subjects will be followed closely with signs and symptoms recorded in a daily log, as well as complete blood counts and research blood collected for one cycle prior to administration of mepolizumab. Subjects will receive a total of 3 administrations of mepolizumab, one infusion every 4-6 weeks, and have a follow-up visit 4 weeks after the last administration of mepolizumab.
The primary efficacy endpoint will be reduction of symptoms and severity of symptoms after mepolizumab. Secondary endpoints will include reduction in peak eosinophils after mepolizumab, continued suppression of absolute eosinophil count and reduction in symptoms following monthly dosing of mepolizumab therapy.
Rendez-vous
| Dernière vérification: | 09/30/2019 |
| Première soumission: | 10/14/2019 |
| Inscription estimée soumise: | 10/14/2019 |
| Première publication: | 10/15/2019 |
| Dernière mise à jour soumise: | 11/14/2019 |
| Dernière mise à jour publiée: | 11/17/2019 |
| Date de début réelle de l'étude: | 11/30/2019 |
| Date d'achèvement primaire estimée: | 03/30/2022 |
| Date estimée d'achèvement de l'étude: | 03/30/2022 |
Condition ou maladie
Intervention / traitement
Biological: 1
Phase
Groupes d'armes
| Bras | Intervention / traitement |
|---|---|
| Experimental: 1 Subjects will receive mepolizumab 700 mg IV x 3 doses at approximately one month intervals, at predicted eosinophil nadir (2-3 weeks after peak), at study visits 4, 6, and 7. | Biological: 1 Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials will be reconstituted with 1.2 ml sterile water for injection (according to the product labeling) and secondarily diluted in 100-250 ml of 0.9% normal saline (NaCl) for infusion (to a final concentration of 0.3-7.5 mg/ml). |
Critère d'éligibilité
| Âges éligibles aux études | 18 Years À 18 Years |
| Sexes éligibles à l'étude | All |
| Accepte les bénévoles en santé | Oui |
| Critères | - INCLUSION CRITERIA: A subject will be eligible for participation in the study only if all of the following criteria apply: 1. The subject is male or female, aged 18 years or older. 2. The subject has a documented diagnosis of EAE. 3. The subject has symptoms of EAE in the cycle prior to screening, including but not limited to fever, swelling, hives or rashes, weight gain, muscle pain, and lymphadenopathy. 4. Cycling of eosinophils is ongoing as indicated by a peak AEC greater than or equal to 1500/mm^3 during at least one cycle in the prior 3 months. 5. If taking corticosteroids, the subject is able and willing to stay on a stable dose for 6 weeks prior to screening. 6. The subject agrees to storage of study samples. 7. The subject is able to provide informed consent. 8. Females are eligible for this study if they are: - of non-childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal as defined by no menses in 1 year); OR - of childbearing potential but willing to practice effective contraception or abstinence during administration of the study drug and for 100 days (5 terminal half-lives) after administration of the investigational study drug. - Not breastfeeding. Participation of Women: Pregnancy: The effects of mepolizumab on the developing human fetus are unknown. For this reason, women of childbearing potential must agree to use adequate contraception (see below for acceptable methods) prior to study entry, for the duration of study participation, and for >5 terminal half-lives (approximately 100 days) after administration of the last dose of study drug. Nonreproductive potential is defined as post-menopausal, male partner who has azoospermia or is surgically sterile (at least 6 weeks before screening) and is the sole sexual partner, surgical sterility, or a congenital or acquired condition that definitely prevents conception. Further, postmenopausal is defined as at least 12 consecutive months with no menses at age 50 or older, or a high follicle-stimulating hormone level in the postmenopausal range at ages 45-50 years in subjects not using hormonal contraception or hormone replacement therapy. Females with reproductive potential must either practice complete and uninterrupted abstinence from heterosexual activity or use 2 of the following methods of contraception with their partners. The 2 methods must include either 2 barrier methods, or 1 barrier method and 1 non-barrier method, both of which must be consistently used: Barrier Methods: 1. Diaphragm with spermicide 2. Cervical cap with spermicide or contraceptive sponge (for nulliparous subjects only) 3. Male or female condom (cannot be used together) Non-Barrier Methods 1. An intrauterine device with a documented failure rate of <1% 2. Hormonal contraception: pill (estrogen/progestin or progestin-only), patch, vaginal ring, rod implanted in the skin, or subcutaneous injection methods Females of childbearing-potential must have a negative pregnancy test result prior to receiving mepolizumab at each visit. During the course of the study, if a woman becomes pregnant or suspects she is pregnant, she should inform the study staff and her primary care physician immediately. A pregnancy registry has been created for subjects who become pregnant while receiving the approved dose of mepolizumab (100 mg subcutaneous injection) for asthma. Fertility: There is no fertility data in humans. Animal studies showed no adverse effects of anti-IL-5 treatment on fertility. EXCLUSION CRITERIA: A subject will not be eligible to participate in the study if any of the following conditions are fulfilled at the time of screening: 1. Treatment with immunosuppressive or immunomodulatory agents including but not limited to cyclosporine, interferon-alpha, azathioprine, methotrexate, and cyclophosphamide within the past 3 months. 2. Treatment with biologics including but not limited to mepolizumab, IVIG, anti-TNF agents, rituximab, benralizumab, alemtuzumab, reslizumab, dupilumab, lebrikizumab, and omalizumab within 6 months or 5 half-lives (whichever is longer). Subjects who received rituximab at any time in the past must have normal B-cell numbers to participate. 3. Co-morbid illness, alcohol or substance abuse, or any other condition (e.g., HIV, active hepatitis) that, in the opinion of the investigator, places the subject at undue risk by participating in the study. Co-enrollment Guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies or those evaluating the use of a licensed medication. Study staff should be notified of co-enrollment as it may require the approval of the investigator. |
Résultat
Mesures des résultats primaires
1. Reduction in the number and severity of clinical symptoms associated with EAE after 3 doses of mepolizumab (as compared to symptoms logged in the approximately monthly cycle preceding initiation of mepolizumab). [Visit 8]
Mesures des résultats secondaires
1. Sustained reduction of eosinophilia after administration of mepolizumab (at Visit 8). [Visit 8]
2. A =75% reduction in peak blood eosinophil count following the first dose of mepolizumab (as compared to the peak eosinophil count in the cycle preceding initiation of mepolizumab therapy). [Visits 3 and 4]
